Develops diagnostic tests for lymphoid cancers and autoimmune diseases.
Jun 2026Revenue $308M/yrExpenses $346M/yr
No trendCash runway over 10 years from Jun 2026
Figures by year
When will Adaptive Biotechnologies be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Jun 2026, revenue was $308M and expenses $346M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $277M | $334M | −$57.1M |
| Dec 2024 | $179M | $342M | −$163M |
| Dec 2023 | $170M | $397M | −$227M |
| Dec 2022 | $185M | $385M | −$200M |
| Dec 2021 | $154M | $363M | −$209M |
| Dec 2020 | $98.4M | $251M | −$153M |
| Dec 2019 | $85.1M | $163M | −$78.4M |
| Dec 2018 | $55.7M | $105M | −$49.8M |
| Dec 2017 | $38.4M | $82.9M | −$44.5M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.